Issued on behalf of VentriPoint Diagnostics Ltd.
An MRI-equivalent cardiac volumetric measurement platform that runs on any ultrasound system worldwide just stacked three validation gates inside thirty days — and the cardiology procurement environment is reorganizing around exactly the kind of evidence stack the Company has been building.
TORONTO, ON, May 26, 2026 — Baystreet News Commentary — Cardiology has emerged as one of the proving grounds for medical artificial intelligence, and the procurement environment around it has shifted hard over the past twelve months. Hospital networks are no longer content to evaluate clinical accuracy in isolation — they want department-level economic proof, vendor-agnostic deployment, and a stacked regulatory and reimbursement story before deployment contracts get signed.
Inside that landscape, VentriPoint Diagnostics Ltd. (TSXV: VPT) (OTC: VPTDF), Butterfly Network, Inc. (NYSE: BFLY), Tempus AI, Inc. (NASDAQ: TEM), RadNet, Inc. (NASDAQ: RDNT), and Heartflow, Inc. (NASDAQ: HTFL) collectively span the spectrum from emerging medtech vendor to established healthcare-AI infrastructure platform.
VentriPoint Diagnostics Ltd. (TSXV: VPT) (OTC: VPTDF) on April 28, 2026 announced that its strategic partner Lishman Global Inc. formally submitted the Company's VMS+™ 4.0 system to China's National Medical Products Administration (NMPA) — the regulatory body commonly referred to as the Chinese FDA — for regulatory approval. Importantly, Lishman Global has qualified for the NMPA's "green channel" pathway — an expedited review process designed to accelerate the approval of innovative medical technologies that address significant clinical needs. The filing is the principal regulatory gating event for VMS+™ access to the Chinese cardiology market.
Paul Gibson, Chief Technology Officer of Lishman Global Inc., framed the submission as a critical step toward bringing VMS+™ 4.0 to the Chinese market, noting that qualification for the NMPA's green channel underscores the clinical relevance and innovation of the platform and provides a clear pathway to accelerated adoption. China's scale, combined with its increasing focus on improving cardiovascular outcomes, places the country at the centre of medical AI procurement engagement through 2026 and into 2027. VentriPoint's strategic partnership with Lishman Global — including the previously announced July 2025 non-binding term sheet covering license terms — provides the commercial vehicle for VMS+™ deployment across the People's Republic of China including Hong Kong and Macao.
Alongside the NMPA regulatory submission, VentriPoint's April–May 2026 sequence has stacked validation across multiple fronts. The VMS+™ 4.0 system collected a 2026 Edison Award Gold Medal — a leading global recognition of innovation often described as "the Oscars of Innovation" — and was scheduled for exhibition at the 59th Annual Meeting of the Association for European Paediatric and Congenital Cardiology (AEPC) in Padua, Italy, May 12–16, 2026. The Company also announced a commercial agreement with LG Consulting Solutions to support deployment of VMS+™ across Northern California, and a partnership with the Nisg_a'a Nation delivering AI 3D heart mapping into Indigenous community healthcare settings.
The technical foundation under the platform is differentiated. VentriPoint applies proprietary Knowledge Based Reconstruction (KBR) technology to standard 2D echocardiograms and produces volumetric cardiac measurements that the Company describes as equivalent in accuracy to magnetic resonance imaging — and it does so on ultrasound systems that already sit in hospitals worldwide, regardless of vendor. The platform supports diagnosis and management of congenital heart defects, heart failure, pulmonary hypertension, cardiotoxicity, and valvular disease. The FDA cleared VMS+ 4.0 via the 510(k) pathway in February 2025, providing the U.S. regulatory baseline against which the NMPA submission and other geographies are now being stacked.
VentriPoint's commercial trajectory through the first half of 2026 reflects the converging procurement environment: hospital networks evaluating AI cardiac imaging are increasingly looking for vendor-agnostic deployment, MRI-equivalent clinical evidence, accelerated regulatory pathways across geographies, and the kind of partnership-and-recognition signal stack that the Company has assembled. With NMPA green-channel review now underway, the Edison Award in hand, AEPC exhibition completed, and Northern California deployment partnership signed, the Company has positioned VMS+™ 4.0 at the intersection of AI-driven diagnostics and the cardiac imaging procurement cycle. For more company information, visit This Link.
In other industry developments and happenings in the market include:
Butterfly Network, Inc. (NYSE: BFLY) has continued to expand its handheld ultrasound and AI-driven imaging platform through 2026, with the Butterfly iQ3 and software platform addressing point-of-care imaging across multiple clinical specialties. Recent quarterly results reflected the Company's continued growth across hospital, clinic, and educational customer segments — alongside ongoing software platform monetization initiatives. Butterfly's positioning at the device-and-software intersection provides a complementary architectural reference to the platform-software approach VentriPoint occupies.
Butterfly's hardware-plus-software model and VentriPoint's vendor-agnostic software-only approach represent two distinct architectural strategies inside the same broader medical ultrasound and AI imaging procurement environment. As hospital procurement evaluates the multi-vendor, multi-modality reality of installed-base ultrasound systems, the software-platform approach — which works across the existing fleet of ultrasound machines from any vendor — has emerged as a structurally differentiated category.
Tempus AI, Inc. (NASDAQ: TEM) continued to scale its AI-driven precision medicine platform through 2026, with sustained growth in genomics and data licensing revenue. The Company's platform combines clinical, molecular, and imaging data to power AI applications across oncology, cardiology, and other therapeutic areas. Recent quarterly results have reinforced the institutional thesis around AI-enabled clinical data infrastructure, with Tempus emerging as one of the most institutionally tracked names in the medical AI category.
Tempus's data-platform positioning at the infrastructure tier of medical AI provides the architectural context within which point-solution vendors like VentriPoint operate. As clinical data infrastructure and clinical decision support platforms scale, the room for specialist clinical AI vendors at the imaging-modality level — particularly those with vendor-agnostic deployment and accelerated international regulatory pathways — has continued to expand inside the broader procurement environment.
RadNet, Inc. (NASDAQ: RDNT) has continued to expand its outpatient diagnostic imaging operations and its AI software subsidiary through 2026. The Company's combination of physical imaging-center infrastructure across major U.S. markets and its growing portfolio of AI-driven clinical software — across breast cancer, prostate cancer, and lung cancer screening categories — places RDNT at the intersection of the diagnostic services and clinical AI segments.
RadNet's combined imaging-services-and-AI-software business model provides operational scale and a structural distribution channel for AI clinical tools across U.S. outpatient diagnostic imaging. The Company's continued investment in AI software development reinforces the broader procurement validation that specialty AI imaging tools — including cardiac AI platforms — have become essential operational components of modern diagnostic imaging workflows.
Heartflow, Inc. (NASDAQ: HTFL) has continued to advance its AI-driven non-invasive cardiac diagnostics platform through 2026, with the HeartFlow FFRct Analysis providing a clinical decision-support tool for coronary artery disease evaluation. The Company's commercial deployment across U.S. and international cardiology centers — together with its IPO in 2025 — has placed HTFL as one of the most directly comparable public-market references for AI-driven cardiac imaging diagnostics.
Heartflow's commercial trajectory and the procurement-tier validation around AI cardiac diagnostics provides the public-market benchmark against which smaller-cap cardiac AI platforms — including VentriPoint's VMS+™ — are increasingly being evaluated. As the AI cardiac imaging procurement environment continues to consolidate around vendor-agnostic deployment, accelerated regulatory pathways, and clinical-evidence-driven adoption, the structural runway for specialist platforms with differentiated technical and partnership stacks has continued to widen.
Across the comparable set, the message is consistent: the cardiac AI procurement environment is reorganizing around evidence stacks — regulatory, commercial, clinical, and partnership — and the vendors converting that procurement environment into recurring revenue are the ones publishing the validation. VentriPoint Diagnostics' April 28 NMPA green-channel submission via Lishman Global, the 2026 Edison Award Gold Medal recognition, the AEPC Padua exhibition, the LG Consulting Northern California partnership, and the Nisg_a'a Indigenous-health partnership collectively form one of the most credible procurement-tier validation sequences a small-cap cardiac AI vendor has presented to the public markets this year. For investors building exposure to the AI cardiac imaging procurement cycle, VPT deserves a closer look.
CONTINUED… Read this and more news for VentriPoint Diagnostics Ltd. at: https://usanewsgroup.com/vpt-landing/
CONTACT:
Baystreet.ca
info@baystreet.ca
604-265-2873
Article Sources:
[1] https://www.prnewswire.com/news-releases/cardiac-ai-diagnostics-stack-validation-wins-across-regulatory-and-commercial-fronts-302775850.html
[2] https://investingnews.com/ventripoint-s-vms-4-0-submitted-for-regulatory-approval-in-china-by-lishman-global-inc/
[3] https://www.globenewswire.com/news-release/2026/05/13/3294035/0/en/A-Toronto-AI-Cardiac-Diagnostics-Company-Just-Cleared-Three-of-the-Hardest-Validation-Bars-in-Medtech.html
[4] https://investors.butterflynetwork.com/news-releases
[5] https://investors.tempus.com/news
[6] https://investors.radnet.com/news-releases
[7] https://investors.heartflow.com/news
DISCLAIMER:
Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. Baystreet.ca is owned by Baystreet.ca Media Corp. (BAY). BAY has been paid a fee of for Ventripoint Diagnostics Ltd. advertising and digital media for this article. There may be 3rd parties who may have shares of Ventripoint Diagnostics Ltd., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator (BAY); reserve the right to buy and sell, and will buy and sell shares of Ventripoint Diagnostics Ltd. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by BAY has been approved by Ventripoint Diagnostics Ltd. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
Related Stories
